CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
Open accessAbstract
Clinical development of chimeric antigen receptor (CAR)-T-cell therapy has been enabled by advances in synthetic biology, genetic engineering, clinical-grade manufacturing, and complex logistics to distribute the drug product to treatment sites. A key ambition of the CARAMBA project is to provide clinical proof-of-concept for virus-free CAR gene transfer using advanced Sleeping Beauty (SB) transposon technology. SB transposition in CAR-T engineering is attractive due to the high rate of stable CAR gene transfer enabled by optimized hyperactive SB100X transposase and transposon combinations, encoded by mRNA and minicircle DNA, respectively, as preferred vector embodiments. This approach bears the potential to facilitate and expedite vector procurement, CAR-T manufacturing and distribution, and the promise to provide a safe, effective, and economically sustainable treatment. As an exemplary and novel target for SB-based CAR-T cells, the CARAMBA consortium has selected the SLAMF7 antigen in multiple myeloma. SLAMF7 CAR-T cells confer potent and consistent anti-myeloma activity in preclinical assays in vitro and in vivo. The CARAMBA clinical trial (Phase-I/IIA; EudraCT: 2019-001264-30) investigates the feasibility, safety, and anti-myeloma efficacy of autologous SLAMF7 CAR-T cells. CARAMBA is the first clinical trial with virus-free CAR-T cells in Europe, and the first clinical trial that uses advanced SB technology worldwide.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
SCFA-treatment during CTL manufacturing can readily be implemented in clinical-grade GMP manufacturing processes.
“SCFA-treatment during CTL manufacturing, which can readily be implemented in clinical-grade GMP manufacturing processes44.”
From Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer (2021) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The origin and behavior of mutable loci in maize
McClintock, B. (1950) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.36.6.344 · Cited by 1,752 · see citing works
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730 · see citing works
Ivics, Z., Hackett, P. B., Plasterk, R. H. A., & Izsvák, Z. (1997) · Cell · doi:10.1016/s0092-8674(00)80436-5 · Cited by 1,431 · see citing works
Self-citationKawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,234 · see citing works
Mátés, L., Chuah, M., Belay, E., Jerchow, B., Manoj, N., Acosta‐Sanchez, A., Grzela, D. P., Schmitt, A., Becker, K., Mátrai, J., et al. (2009) · Nature Genetics · doi:10.1038/ng.343 · Cited by 951 · see citing works
Self-citationSommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2015) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 864 · see citing works
Self-citationAli, S. A., Shi, V., Marić, I., Wang, M. L., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler‐Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 760 · see citing works
Wang, X., Chang, W.-C., Wong, C. W., Colcher, D. M., Sherman, M. A., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600 · see citing works
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Hsi, E. D., Steinle, R., Balasa, B., Szmania, S. M., Draksharapu, A., Shum, B. P., Huseni, M. A., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 558 · see citing works
Yant, S. R., Meuse, L. A., Chiu, W. S., Ivics, Z., Izsvák, Z., & Kay, M. A. (2000) · Nature Genetics · doi:10.1038/75568 · Cited by 509 · see citing works
Self-citationPhase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Kebriaei, P., Singh, H., Huls, M. H., Figliola, M. J., Bassett, R. L., Olivares, S., Jena, B., Dawson, M. J., Kumaresan, P. R., Su, S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86721 · Cited by 501 · see citing works
Tai, Y., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2007) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 472 · see citing works
Sinn, P., Sauter, S., & McCray, P. B. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302570 · Cited by 351 · see citing works
Recent Advances in Lentiviral Vector Development and Applications
Mátrai, J., Chuah, M., & VandenDriessche, T. (2010) · Molecular Therapy · doi:10.1038/mt.2009.319 · Cited by 349 · see citing works
Izsvák, Z., Ivics, Z., & Plasterk, R. H. A. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4047 · Cited by 332 · see citing works
Self-citationPont, M. J., Hill, T., Cole, G. O., Abbott, J. J., Kelliher, J. L., Salter, A. I., Hudecek, M., Comstock, M., Rajan, A., Patel, B. K. R., et al. (2019) · Blood · doi:10.1182/blood.2019000050 · Cited by 332 · see citing works
Self-citationTransposon-mediated Genome Manipulations in Vertebrates
Ivics, Z., Li, M., Mátés, L., Boeke, J., Nagy, A., Bradley, A., & Izsvák, Z. (2009) · Nature Methods · doi:10.1038/nmeth.1332 · Cited by 318 · see citing works
Self-citationMonjezi, R., Miskey, C., Gogishvili, T., Schleef, M., Schmeer, M., Einsele, H., Ivics, Z., & Hudecek, M. (2016) · Leukemia · doi:10.1038/leu.2016.180 · Cited by 260 · see citing works
Self-citationSleeping beauty transposition: biology and applications for molecular therapy.
Izsvák, Z., & Ivics, Z. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.11.009 · Cited by 251 · see citing works
Self-citationA new DNA vehicle for nonviral gene delivery: supercoiled minicircle
Darquet, A.-M., Cameron, B., Wils, P., Scherman, D., & Crouzet, J. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300540 · Cited by 250 · see citing works
Development of Hyperactive Sleeping Beauty Transposon Vectors by Mutational Analysis
Zayed, H., Izsvák, Z., Walisko, O., & Ivics, Z. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.11.024 · Cited by 250 · see citing works
Self-citationSLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes
Gogishvili, T., Danhof, S., Prommersberger, S., Rydzek, J., Schreder, M., Brede, C., Einsele, H., & Hudecek, M. (2017) · Blood · doi:10.1182/blood-2017-04-778423 · Cited by 241 · see citing works
Self-citationHartman, Z. C., Appledorn, D. M., & Amalfitano, A. (2008) · Virus Research · doi:10.1016/j.virusres.2007.10.005 · Cited by 239 · see citing works
A Transposon and Transposase System for Human Application
Hackett, P. B., Largaespada, D. A., & Cooper, L. J. N. (2010) · Molecular Therapy · doi:10.1038/mt.2010.2 · Cited by 205 · see citing works
Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities
Magnani, C. F., Gaipa, G., Lussana, F., Belotti, D., Gritti, G., Napolitano, S., Matera, G., Cabiati, B., Buracchi, C., Borleri, G., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138473 · Cited by 193 · see citing works
Gogol‐Döring, A., Ammar, I., Gupta, S., Bunse, M., Miskey, C., Chen, W., Uckert, W., Schulz, T. F., Izsvák, Z., & Ivics, Z. (2016) · Molecular Therapy · doi:10.1038/mt.2016.11 · Cited by 161 · see citing works
Self-citationEmerging potential of transposons for gene therapy and generation of induced pluripotent stem cells
VandenDriessche, T., Ivics, Z., Izsvák, Z., & Chuah, M. (2009) · Blood · doi:10.1182/blood-2009-04-210427 · Cited by 150 · see citing works
Self-citationTargeted Sleeping Beauty transposition in human cells.
Ivics, Z., Katzer, A., Stüwe, E. E., Fiedler, D., Knespel, S., & Izsvák, Z. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300169 · Cited by 149 · see citing works
Self-citationTransposon-mediated BAC transgenesis in human ES cells
Rostovskaya, M., Fu, J., Obst, M., Baer, I., Weidlich, S., Wang, H., Smith, A. J. H., Anastassiadis, K., & Stewart, A. F. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks643 · Cited by 143 · see citing works
The Sleeping Beauty transposon system: a non-viral vector for gene therapy
Aronovich, E. L., McIvor, R. S., & Hackett, P. B. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr140 · Cited by 143 · see citing works
Sleeping beauty transposon-mediated gene therapy for prolonged expression.
Hackett, P. B., Ekker, S. C., Largaespada, D., & McIvor, R. (2005) · Advances in Genetics · doi:10.1016/s0065-2660(05)54009-4 · Cited by 136 · see citing works
The expanding universe of transposon technologies for gene and cell engineering
Ivics, Z., & Izsvák, Z. (2010) · Mobile DNA · doi:10.1186/1759-8753-1-25 · Cited by 130 · see citing works
Self-citationXue, X., Huang, X., Nodland, S. E., Mátés, L., Ma, L., Izsvák, Z., Ivics, Z., LeBien, T. W., McIvor, R. S., Wagner, J. E., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210005 · Cited by 126 · see citing works
Self-citationGene Therapy with the Sleeping Beauty Transposon System
Kebriaei, P., Izsvák, Z., Narayanavari, S. A., Singh, H., & Ivics, Z. (2017) · Trends in Genetics · doi:10.1016/j.tig.2017.08.008 · Cited by 124 · see citing works
Self-citationIvics, Z., & Izsvák, Z. (2006) · Current Gene Therapy · doi:10.2174/156652306778520647 · Cited by 114 · see citing works
Self-citationTranslating Sleeping Beauty transposition into cellular therapies: Victories and challenges
Izsvák, Z., Hackett, P. B., Cooper, L. J. N., & Ivics, Z. (2010) · BioEssays · doi:10.1002/bies.201000027 · Cited by 112 · see citing works
Self-citationEvaluating risks of insertional mutagenesis by DNA transposons in gene therapy
Hackett, P. B., Largaespada, D. A., Switzer, K. C., & Cooper, L. J. N. (2013) · Translational research · doi:10.1016/j.trsl.2012.12.005 · Cited by 96 · see citing works
Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side
Hudecek, M., Izsvák, Z., Johnen, S., Renner, M., Thumann, G., & Ivics, Z. (2017) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2017.1304354 · Cited by 94 · see citing works
Self-citationWalisko, O., Schorn, A. J., Rolfs, F., Devaraj, A., Miskey, C., Izsvák, Z., & Ivics, Z. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300366 · Cited by 93 · see citing works
Self-citationA highly soluble Sleeping Beauty transposase improves control of gene insertion
Querques, I., Mades, A., Zuliani, C., Miskey, C., Alb, M., Grueso, E., Machwirth, M., Rausch, T., Einsele, H., Ivics, Z., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0291-z · Cited by 91 · see citing works
Self-citationAdeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0052-2014 · Cited by 88 · see citing works
Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors
Hirsch, M. L., Wolf, S., & Samulski, R. J. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3271-9_2 · Cited by 84 · see citing works
Minicircle DNA electrotransfer for efficient tissue-targeted gene delivery
Chabot, S., Orio, J., Schmeer, M., Schleef, M., Golzio, M., & Teissié, J. (2012) · Gene Therapy · doi:10.1038/gt.2011.215 · Cited by 75 · see citing works
Holstein, M., Mesa-Núñez, C., Miskey, C., Almarza, E., Poletti, V., Schmeer, M., Grueso, E., Flores, J. C. O., Kobelt, D., Walther, W., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.012 · Cited by 73 · see citing works
Self-citationmRNA‐Mediated Gene Delivery Into Human Progenitor Cells Promotes Highly Efficient Protein Expression
Wiehe, J. M., Ponsaerts, P., Rojewski, M., Homann, J. M., Greiner, J., Kronawitter, D., Schrezenmeier, H., Hombach, V., Wiesneth, M., Zimmermann, O., et al. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00038.x · Cited by 67 · see citing works
Nonviral Gene Delivery with the Sleeping Beauty Transposon System
Ivics, Z., & Izsvák, Z. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.143 · Cited by 61 · see citing works
Self-citationNon-viral therapeutic cell engineering with the Sleeping Beauty transposon system
Hudecek, M., & Ivics, Z. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.06.003 · Cited by 61 · see citing works
Self-citationHackett, P. B., Aronovich, E. L., Hunter, D. W., Urness, M., Bell, J. B., Kass, S. J., Cooper, L. J. N., & McIvor, S. R. (2011) · Current Gene Therapy · doi:10.2174/156652311797415827 · Cited by 53 · see citing works
Sleeping Beauty transposition: from biology to applications
Narayanavari, S. A., Chilkunda, S. S., Ivics, Z., & Izsvák, Z. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2016.1237935 · Cited by 53 · see citing works
Self-citationAwakening gene therapy with Sleeping Beauty transposons.
Essner, J. J., McIvor, R., & Hackett, P. (2005) · Current opinion in pharmacology (Print) · doi:10.1016/j.coph.2005.04.015 · Cited by 48 · see citing works
Amberger, M., & Ivics, Z. (2020) · BioEssays · doi:10.1002/bies.202000136 · Cited by 48 · see citing works
Self-citationMoldt, B., Yant, S. R., Andersen, P. R., Kay, M. A., & Mikkelsen, J. G. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.099 · Cited by 43 · see citing works
Efficient Sleeping Beauty DNA Transposition From DNA Minicircles
Sharma, N., Cai, Y., Bak, R. O., Jakobsen, M. R., Schrøder, L. D., & Mikkelsen, J. G. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.1 · Cited by 34 · see citing works
Loperfido, M., Jarmin, S., Dastidar, S., Matteo, M. D., Perini, I., Moore, M., Nair, N., Samara-Kuko, E., Athanasopoulos, T., Tedesco, F. S., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1464 · Cited by 28 · see citing works
Boehme, P., Doerner, J., Solanki, M., Liu, J., Zhang, W., & Ehrhardt, A. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150126121353 · Cited by 23 · see citing works
Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells
Hudecek, M., Gogishvili, T., Monjezi, R., Wegner, J., Shankar, R., Krüsemann, C., Miskey, C., Ivics, Z., Schmeer, M., & Schleef, M. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42934-2_3 · Cited by 19 · see citing works
Self-citationHose, D., Schreder, M., Hefner, J., Bittrich, M., Danhof, S., Strifler, S., Krauth, M., Schoder, R., Gisslinger, B., Einsele, H., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03323-6 · Cited by 14 · see citing works
Self-citationZhong, Q., Zhu, Y., Zheng, L., Shen, H., Ou, R., Liu, Z., She, Y., Chen, R., Li, C., Huang, J., et al. (2018) · Acta Haematologica · doi:10.1159/000492146 · Cited by 13 · see citing works
Miskey, C., Amberger, M., Reiser, M., Prommersberger, S., Beckmann, J., Machwirth, M., Einsele, H., Hudecek, M., Bonig, H. B., & Ivics, Z. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/675009 · Cited by 10 · see citing works
Self-citationSleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates
Izsvak, Z., Ivics, Z., & Plasterk, R. H. A. (2000) · MDC Repository (Max-Delbrueck-Center for Molecular Medicine) · Cited by 8 · see citing works
Self-citationClauss, J., Obenaus, M., Miskey, C., Ivics, Z., Izsvák, Z., Uckert, W., & Bunse, M. (2018) · MDC Repository (Max-Delbrueck-Center for Molecular Medicine) · doi:10.1089/hum.2017.136 · Cited by 1 · see citing works
Self-citation
Flagged first, then by citations
1 of the 62 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Luu, M., Riester, Z., Baldrich, A., Reichardt, N., Yuille, S., Busetti, A., Klein, M., Wempe, A., Leister, H., Raifer, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24331-1 · Cited by 771 · see citing works
Self-citationCAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927153 · Cited by 416 · see citing works
CAR-T cell manufacturing: Major process parameters and next-generation strategies
Ceja, M. A., Khericha, M., Harris, C., Puig-Saus, C., & Chen, Y. (2024) · Journal of Experimental Medicine · doi:10.1084/jem.20230903 · Cited by 293 · see citing works
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment
Bui, T. A., Mei, H., Sang, R., Ortega, D., & Deng, W. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105266 · Cited by 168 · see citing works
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
Zhang, X., Zhang, H., Lan, H., Wu, J., & Xiao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1101495 · Cited by 173 · see citing works
The Past, Present, and Future of Non-Viral CAR T Cells
Moretti, A., Ponzo, M., Nicolette, C. A., Tcherepanova, I. Y., Biondi, A., & Magnani, C. F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867013 · Cited by 159 · see citing works
Sandoval-Villegas, N., Nurieva, W., Amberger, M., & Ivics, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105084 · Cited by 142 · see citing works
Self-citationSystematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input
Wang, V., Gauthier, M., Decot, V., Reppel, L., & Bensoussan, D. (2023) · Cancers · doi:10.3390/cancers15041003 · Cited by 124 · see citing works
Seif, M., Kakoschke, T. K., Ebel, F., Bellet, M. M., Trinks, N., Renga, G., Pariano, M., Romani, L. R., Tappe, B., Espie, D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abh1209 · Cited by 112 · see citing works
Self-citationIrving, M., Lanitis, E., Migliorini, D., Ivics, Z., & Guedan, S. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.173 · Cited by 86 · see citing works
Self-citationParikh, R. H., & Lonial, S. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21771 · Cited by 105 · see citing works
The EBMT/EHA CAR-T Cell Handbook
Kröger, N., Gribben, J. G., Chabannon, C., Yakoub‐Agha, I., & Einsele, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0 · Cited by 99 · see citing works
Self-citationDerraz, B., Breda, G., Kaempf, C., Baenke, F., Cotte, F., Reiche, K., Köhl, U., Kather, J. N., Eskenazy, D., & Gilbert, S. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00517-w · Cited by 94 · see citing works
Tipanee, J., Samara-Kuko, E., Gevaert, T., Chuah, M. K., & VandenDriessche, T. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.006 · Cited by 76 · see citing works
Hiltensperger, M., & Krackhardt, A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121030 · Cited by 78 · see citing works
Non-viral chimeric antigen receptor (CAR) T cells going viral
Balke-Want, H., Keerthi, V., Cadinanos-Garai, A., Fowler, C., Gkitsas, N., Brown, A. K., Tunuguntla, R. H., Abouelenein, M., & Feldman, S. A. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100375 · Cited by 72 · see citing works
Li, W., Zhang, B., Cao, W., Zhang, W., Li, T., Liu, L., Xu, L., Gao, F., Wang, Y., Wang, F., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00402-5 · Cited by 63 · see citing works
The Black Hole: CAR T Cell Therapy in AML
Atilla, E., & Benabdellah, K. (2023) · Cancers · doi:10.3390/cancers15102713 · Cited by 64 · see citing works
Recent advances in therapeutic gene-editing technologies
Liu, D., Cao, D., & Han, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.026 · Cited by 62 · see citing works
Bexte, T., Botezatu, L., Miskey, C., Gierschek, F., Moter, A., Wendel, P., Reindl, L. M., Campe, J., Villena-Ossa, J. F., Gebel, V., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.022 · Cited by 54 · see citing works
Self-citationSteffin, D., Muhsen, I. N., Hill, L. C., Ramos, C. A., Ahmed, N. M., Hegde, M. G., Wang, T., Wu, M.-F., Gottschalk, S. M., Whittle, S. B., et al. (2022) · Blood · doi:10.1182/blood.2022015728 · Cited by 52 · see citing works
NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development
Dezfouli, A. B., Yazdi, M., Pockley, A. G., Khosravi, M., Kobold, S., Wagner, E., & Multhoff, G. (2021) · Cells · doi:10.3390/cells10123390 · Cited by 51 · see citing works
Ruppel, K. E., Fricke, S., Köhl, U., & Schmiedel, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.822298 · Cited by 46 · see citing works
Automated, scaled, transposon-based production of CAR T cells
Lock, D., Monjezi, R., Brandes, C., Bates, S., Lennartz, S., Teppert, K., Gehrke, L., Karasakalidou-Seidt, R., Lukic, T., Schmeer, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005189 · Cited by 45 · see citing works
Self-citationO’Neal, J., Ritchey, J., Cooper, M. L., Niswonger, J., González, L. S., Street, E., Rettig, M. P., Gladney, S., Gehrs, L., Abboud, R., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01559-4 · Cited by 50 · see citing works
Cost-effective strategies for CAR-T cell therapy manufacturing
Abdo, L., Batista-Silva, L., & Bonamino, M. (2025) · Molecular therapy. Oncology · doi:10.1016/j.omton.2025.200980 · Cited by 58 · see citing works
Golikova, E., Alshevskaya, A., Alrhmoun, S., Sivitskaya, N., & Sennikov, S. V. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05703-9 · Cited by 42 · see citing works
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
Larson, R. C., Kann, M. C., Graham, C., Mount, C., Castaño, A. P., Lee, W., Bouffard, A. A., Takei, H. N., Almazan, A. J., Scarfò, I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43416-7 · Cited by 48 · see citing works
Metanat, Y., Viktor, P., Amajd, A., Kaur, I., Hamed, A. M., Al-Abadi, N. K. A., Alwan, N. H., Chaitanya, M., Natrayan, L., Ghildiyal, P., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122683 · Cited by 48 · see citing works
Wang, M., Krueger, J. B., Gilkey, A. K., Stelljes, E. M., Kluesner, M. G., Pomeroy, E. J., Skeate, J. G., Slipek, N. J., Lahr, W. S., Claudio Vázquez, P. N., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009560 · Cited by 45 · see citing works
Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Yao, L., Wang, J. T., Jayasinghe, R. G., O’Neal, J., Tsai, C., Rettig, M. P., Song, Y., Liu, R., Zhao, Y., Ibrahim, O. M., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1769 · Cited by 42 · see citing works
Current strategies employed in the manipulation of gene expression for clinical purposes
Tsai, H., Pietrobon, V., Peng, M., Wang, S., Zhao, L., Marincola, F. M., & Cai, Q. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03747-3 · Cited by 42 · see citing works
Gurney, M., O'Reilly, E., Corcoran, S. E., Brophy, S., Krawczyk, J., Otto, N., Hermanson, D., Childs, R., Szegezdi, E., & O'Dwyer, M. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.07.008 · Cited by 35 · see citing works
CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
Mishra, A. K., Gupta, A., Dagar, G., Das, D., Chakraborty, A., Haque, S., Prasad, C. P., Singh, A. K., Bhat, A. A., Macha, M. A., et al. (2023) · Vaccines · doi:10.3390/vaccines11111721 · Cited by 40 · see citing works
CAR T-cell therapy in multiple myeloma: mission accomplished?
Rasche, L., Hudecek, M., & Einsele, H. (2023) · Blood · doi:10.1182/blood.2023021221 · Cited by 41 · see citing works
Self-citationVanderBurgh, J. A., Corso, T. N., Levy, S. L., & Craighead, H. G. (2023) · Scientific Reports · doi:10.1038/s41598-023-33941-2 · Cited by 39 · see citing works
Neri, P., Leblay, N., Lee, H., Gullà, A., Bahlis, N. J., & Anderson, K. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00913-y · Cited by 37 · see citing works
SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
Chu, E., Wu, J., Kang, S. S., & Kang, Y. (2023) · Current Oncology · doi:10.3390/curroncol30090573 · Cited by 36 · see citing works
Current Non-Viral-Based Strategies to Manufacture CAR-T Cells
Gehrke, L., Gonçalves, V. D. R., Andrae, D., Raskó, T., Ho, P., Einsele, H., Hudecek, M., & Friedel, S. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413685 · Cited by 32 · see citing works
Self-citationXiao, K., Lai, Y., Yuan, W., Li, S., Liu, X., Xiao, Z., & Xiao, H. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20230036 · Cited by 33 · see citing works
Engineering CAR-T therapies for autoimmune disease and beyond
English, E. P., Swingler, R. N., Patwa, S., Tosun, M., Howard, J. F., Miljković, M. D., & Jewell, C. M. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado2084 · Cited by 32 · see citing works
Asherie, N., Kfir‐Erenfeld, S., Avni, B. R., Assayag, M., Dubnikov, T., Zalcman, N., Lebel, E., Zimran, E., Shaulov, A., Pick, M., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.281628 · Cited by 31 · see citing works
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma
Choi, T., & Kang, Y. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108007 · Cited by 30 · see citing works
Court, A. C., Parra-Crisóstomo, E., Castro-Córdova, P., Abdo, L., Aragão, E., Lorca, R., Figueroa, F. E., Bonamino, M., & Khoury, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05627-4 · Cited by 27 · see citing works
On the road to eliminating long‐lived plasma cells—“are we there yet?”
Markmann, C., & Bhoj, V. G. (2021) · Immunological Reviews · doi:10.1111/imr.13015 · Cited by 27 · see citing works
Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
Maucher, M., Srour, M., Danhof, S., Einsele, H., Hudecek, M., & Yakoub‐Agha, I. (2021) · Cancers · doi:10.3390/cancers13246157 · Cited by 25 · see citing works
Self-citationMechanisms of Action of the New Antibodies in Use in Multiple Myeloma
Romano, A., Storti, P., Marchica, V., Scandura, G., Notarfranchi, L., Craviotto, L., Raimondo, F. D., & Giuliani, N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684561 · Cited by 24 · see citing works
Pérez-Amill, L., Bataller, Á., Delgado, J., Esteve, J., Juan, M., & Klein-González, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1260470 · Cited by 23 · see citing works
Current Novel Targeted Therapeutic Strategies in Multiple Myeloma
Lin, C. H.-T., Tariq, M. J., Ullah, F., Sannareddy, A., Khalid, F., Abbas, H., Bader, A., Samaras, C. J., Valent, J. N., Khouri, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116192 · Cited by 25 · see citing works
Nonviral technologies can pave the way for CAR-NK cell therapy
Bexte, T., Reindl, L. M., & Ullrich, E. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad074 · Cited by 22 · see citing works
Füchsl, F., & Krackhardt, A. M. (2022) · Cells · doi:10.3390/cells11030410 · Cited by 23 · see citing works
Petri, K., D’Ippolito, E., Künkele, A., Koehl, U., Busch, D. H., Einsele, H., & Hudecek, M. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01072-4 · Cited by 23 · see citing works
Self-citationGene knockout in cellular immunotherapy: Application and limitations.
Zhang, X., Jin, X., Sun, R., Zhang, M., Lu, W.-Y., & Zhao, M.-F. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215736 · Cited by 20 · see citing works
Zhou, Z., Chen, Y., Ba, Y., Xu, H., Zuo, A., Liu, S., Zhang, Y., Weng, S., Ren, Y., Luo, P., et al. (2024) · Cell Proliferation · doi:10.1111/cpr.13791 · Cited by 20 · see citing works
mRNA-based therapies: Preclinical and clinical applications
Qureischi, M., Mohr, J., Arellano-Viera, E., Knudsen, S. E., Vohidov, F., & Garitano-Trojaola, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.007 · Cited by 21 · see citing works
Immunotherapy of Multiple Myeloma: Promise and Challenges
Abramson, H. N. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s306103 · Cited by 19 · see citing works
Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies
Polgárová, K., Otáhal, P., Šálek, C., & Pytlík, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.876758 · Cited by 15 · see citing works
Rna-loaded nanoparticles for the treatment of hematological cancers.
Garbayo, E., Moukhtari, S. H. E., Rodríguez-Nogales, C., Agirre, X., Rodríguez-Madoz, J. R., Rodriguez-Marquez, P., Prósper, F., Couvreur, P., & Blanco-Prieto, M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115448 · Cited by 12 · see citing works
Marton, C., Clémenceau, B., Dachy, G., Demerle, C., Derenne, S., Ferrand, C., Giverne, C., Latouche, J.-B., Lemée, L., Martinet, J., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02637-8 · Cited by 16 · see citing works
Self-citationLim, J., Oh, D., Cheng, M., Chintapula, U. K., Liu, S., Reynolds, D., Zhang, X., Zhou, Y., Xu, X., & Ko, J. (2025) · Small · doi:10.1002/smll.202410975 · Cited by 16 · see citing works
CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer
Wei, D., Wang, L., Liu, Y., Zuo, X., Shen, X., & Bresalier, R. S. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1201 · Cited by 16 · see citing works
Current state of CAR-T cell therapies for solid tumors.
Rosa, R., Liu, J.-Y., Lu, C., Abouelenein, M., Murad, J. P., & Priceman, S. (2026) · i Medicina · doi:10.1016/j.medj.2026.101028 · Cited by 19 · see citing works
Accelerating Diverse Cell-Based Therapies Through Scalable Design
Peterman, E. L., Ploessl, D. S., & Galloway, K. E. (2024) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-100722-121610 · Cited by 15 · see citing works
Cancer vaccines: Discovery, development, and challenges for clinical translation
Zhang, Z., Yao, S., Wang, Y., Luo, K., Amiji, M. M., & Anderson, K. C. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123615 · Cited by 15 · see citing works
Wang, S., Gao, B., Miskey, C., Guan, Z., Sang, Y., Chen, C., Wang, X., Ivics, Z., & Song, C. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad005 · Cited by 15 · see citing works
Self-citationNew insights on potency assays from recent advances and discoveries in CAR T-cell therapy
Shao, L., Zheng, Y., Somerville, R. P. T., Stroncek, D. F., & Jin, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1597888 · Cited by 15 · see citing works
Setayesh, S. M., Ndacayisaba, L. J., Rappard, K. E., Hennes, V., Rueda, L. Y. M., Tang, G., Lin, P., Orlowski, R. Z., Symer, D. E., Manasanch, E. E., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00446-0 · Cited by 16 · see citing works
Beyond BCMA: newer immune targets in myeloma
Tan, M. S. Y., Chen, Y., & Smith, E. L. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010856 · Cited by 14 · see citing works
Non-viral vectors for chimeric antigen receptor immunotherapy
Tretbar, S., Rurik, J. G., Rustad, E. H., Sürün, D., Koehl, U., Olweus, J., Buchholz, F., Ivics, Z., Fricke, S., & Blache, U. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00348-w · Cited by 15 · see citing works
Self-citationSignificant Advancements and Evolutions in Chimeric Antigen Receptor Design
Gaimari, A., Lucia, A. D., Nicolini, F., Mazzotti, L., Maltoni, R., Rughi, G., Zurlo, M., Marchesini, M., Juan, M., Parras, D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212201 · Cited by 13 · see citing works
Díez, B., Calviño, C., Fernández-García, M., Rodriguez-Marquez, P., Rodríguez-Díaz, S., Martínez-Turillas, R., Ceballos, C., Illarramendi, J., Serrano-López, J., Miskey, C., et al. (2025) · Molecular Therapy: Methods & Clinical Development · doi:10.1016/j.omtm.2025.101425 · Cited by 12 · see citing works
Self-citationIn vivo nano-engineering T cells for CAR-T therapy
Shi, T., Li, Y., Deng, C., Ren, Q., Xu, C., & Zhong, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114379 · Cited by 13 · see citing works
Zhang, Z., Cui, D., Wang, H., Wu, L., & Liu, X. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04278-8 · Cited by 13 · see citing works
Chabannon, C., Ruggeri, A., Montoto, S., van Biezen, A., van der Werf, S. M., Markslag, A., Sánchez-Ortega, I., de la Cámara, R., Ljungman, P., Mohty, M., et al. (2024) · Baillière's Best Practice & Research: Clinical Haematology · doi:10.1016/j.beha.2024.101557 · Cited by 15 · see citing works
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Yue, T., Sun, Y., Dai, Y., & Jin, F. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101256 · Cited by 14 · see citing works
Schindler-Wnek, K., Stahringer, A., Heimer, N., Koehl, U., Fricke, S., & Schmiedel, D. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2546443 · Cited by 14 · see citing works
Road testing new CAR design strategies in multiple myeloma
Rana, P. S., Murphy, E. V., Kort, J., & Driscoll, J. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.957157 · Cited by 13 · see citing works
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma
Korst, C. L. B. M., O’Neill, C. A., Bruins, W. S. C., Cosovic, M., Twickler, I., Verkleij, C. P. M., Clerre, D. L., Themeli, M., Chion-Sotinel, I., Zweegman, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008769 · Cited by 13 · see citing works
Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens
Rieger, L., Irlinger, K., Füchsl, F., Tietje, M. R., Purcarea, A., Barbian, N., Faber, M., Vogelsang, C., Pfeuffer, L., Stotz, S., et al. (2025) · Blood · doi:10.1182/blood.2024027616 · Cited by 14 · see citing works
Self-citationBCMA CAR-T cells in multiple myeloma–ready for take-off?
Scheller, L., Tebuka, E., Rambau, P., Einsele, H., Hudecek, M., Prommersberger, S., & Danhof, S. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2276676 · Cited by 12 · see citing works
Self-citationEmerging CAR immunotherapies: broadening therapeutic horizons beyond cancer
Sueangoen, N., & Prasongtanakij, S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01820-x · Cited by 14 · see citing works
Point-of-Care Production of CAR-T Cells
Delgado, J., Roddie, C., & Schmitt, M. W. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0_8 · Cited by 11 · see citing works
Multi-targeted immunotherapeutics to treat B cell malignancies
Gambles, M. T., Yang, J., & Kopec̆ek, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.048 · Cited by 11 · see citing works
Fine tuning towards the next generation of engineered T cells
Nguyen, T. T., Ho, P., Staudt, S., Grégoire, C., Ziegler-Martin, K., Jassin, M., Block, A., Hudecek, M., Melenhorst, J. J., Caers, J., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01492-8 · Cited by 11 · see citing works
Self-citationTargeted gene delivery systems for T-cell engineering
Wang, F., Huang, Y., Li, J., Zhou, W., & Wang, W. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00954-6 · Cited by 10 · see citing works
Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma
Sharma, N., & Choudhary, B. (2023) · Biomolecules · doi:10.3390/biom13111629 · Cited by 10 · see citing works
Optimizing CAR-T treatment: A T2EVOLVE guide to raw and starting material selection
Velázquez, S. N., Moukheiber, C., Inogés, S., Guillén, M. R., de Cerio, A. L.-D., Sanges, C., Tanaka, T., Arnould, S., Briones, J., Dolstra, H., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.017 · Cited by 9 · see citing works
Self-citationCAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
Yu, T., Jiao, J., & Wu, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1499590 · Cited by 11 · see citing works
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies
Weirauch, U., Kreuz, M., Birkenbihl, C., Alb, M., Quaranta, M., Calzone, L., Orozco-Ruiz, S., Binder, S., Fischer, L., Clavreul, S., et al. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01809-6 · Cited by 9 · see citing works
Self-citationHua, W., Hsu, J. C., Chen, Y., Chang, P. S., Wen, K. K., Wang, P., Yang, W., Shen, C., Yu, Y., Chen, Y., et al. (2023) · The FASEB Journal · doi:10.1096/fj.202201654r · Cited by 8 · see citing works
Update on the current and future use of CAR‐T to treat multiple myeloma
Gahvari, Z. J., Brunner, M., Schmidt, T. M., & Callander, N. S. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14145 · Cited by 9 · see citing works
Antibiotic-Free Gene Vectors: A 25-Year Journey to Clinical Trials
Marie, C., & Scherman, D. (2024) · Genes · doi:10.3390/genes15030261 · Cited by 7 · see citing works
Integrating Immune Therapies for the Treatment of Multiple Myeloma
Mikkilineni, L., & Sidana, S. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7100 · Cited by 9 · see citing works
Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors
Zingg, A., Ritschard, R., Thut, H., Buchi, M., Holbro, A., Oseledchyk, A., Heinzelmann-Schwarz, V. A., Buser, A. S., Binder, M., Zippelius, A., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1050 · Cited by 8 · see citing works
Biltibo, E. A., & Berdeja, J. G. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.01.017 · Cited by 8 · see citing works
Chang, P. S., Chen, Y.-C., Hua, W.-K., Hsu, J. C., Tsai, J.-C., Huang, Y.-W., Kao, Y.-H., Wu, P.-H., Wang, P.-N., Chang, Y.-F., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309245 · Cited by 7 · see citing works
Regulation of CAR transgene expression to design semiautonomous CAR-T
Głowacki, P., Tręda, C., & Rieske, P. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200833 · Cited by 7 · see citing works
Cellular Therapies for Multiple Myeloma: Engineering Hope
Vera-Cruz, S., Culubret, M., Konetzki, V., Alb, M., Friedel, S. R., Hudecek, M., Einsele, H., Danhof, S., & Scheller, L. (2024) · Cancers · doi:10.3390/cancers16223867 · Cited by 9 · see citing works
Self-citationGeneration of CAR-T Cells with Sleeping Beauty Transposon Gene Transfer
Prommersberger, S., Monjezi, R., Botezatu, L., Miskey, C., Amberger, M., Mestermann, K., Hudecek, M., & Ivics, Z. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2441-8_3 · Cited by 7 · see citing works
Self-citationStraßl, I., & Podar, K. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2319672 · Cited by 8 · see citing works
- Authors
- Prommersberger, S., Reiser, M., Beckmann, J., Danhof, S., Amberger, M., Quade-Lyssy, P., Einsele, H., Hudecek, M., Bonig, H., & Ivics, Z.
- Affiliations
- Universitätsklinikum Würzburg (DE)
- Goethe University Frankfurt (DE)
- Paul Ehrlich Institut (DE)
- Corresponding author
- Ivics, Zoltán
- ORCID
- Venue
- Gene Therapy
- Published
- 2021-04-13
- Volume
- 28
- Issue
- 9
- Pages
- 560-571
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- PMC
- PMC8455317
- OpenAlex
- W3154860673
- Cited by
- 182
- References
- 62
- Citations by year
- 2026: 23 · 2025: 38 · 2024: 43 · 2023: 35 · 2022: 28 · 2021: 15
- FWCI
- 11.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Gene Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by)
- Funders
- EC | Horizon 2020 Framework Programme (754658)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- SLAMF7, chimeric antigen receptor T cells, multiple myeloma, Sleeping Beauty transposon, DNA minicircles
- MeSH terms
- Signaling Lymphocytic Activation Molecule Family, Humans, Multiple Myeloma, T-Lymphocytes, Genetic Therapy, Immunotherapy, Adoptive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
